Comparison of Diagnostic Performance between Abbott Id Now TM & RealTime PCR for the Detection of SARS COV-2 in a Tertiary Care Hospital
Authors/Creators
- 1. Senior Lab Technician, Department of Molecular Virology, Panimalar Medical College Hospital & Research Institute, Chennai
- 2. Assistant Professor, Department of Surgery, Panimalar Medical College Hospital & Research Institute, Chennai
- 3. Assistant Professor, Department of General Medicine, Panimalar Medical College Hospital & Research Institute, Chennai
- 4. Tutor, Department of Molecular Virology, Panimalar Medical College Hospital & Research Institute, Chennai
- 5. Assistant Professor, Department of Microbiology, Panimalar Medical College Hospital & Research Institute, Chennai
- 6. Professor, Department of Microbiology, Panimalar Medical College Hospital & Research Institute, Chennai
- 7. Second year MBBS student, Panimalar Medical College Hospital & Research Institute, Chennai
- 8. Professor, Department of Biochemistry, Panimalar Medical College Hospital & Research Institute, Chennai
Description
Background: The incidence of the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic has posed to be crisis to the diagnostic laboratories around the world for seeking reliable methods to confirm the infection in a short span of time which helps in the treatment plan and also to isolate the patients to prevent the spread. Most of the laboratories presently use Real-Time reverse transcription-Polymerase Chain Reaction (RT-PCR) test to diagnose the infection which has many drawbacks including the need for a dedicated work area, skillful and trained staffs and long testing time. In order to reduce the above constrains; we decided to test the efficiency of Abbott ID Now TM COVID-19 which is a cartridge based nucleic acid amplification assay that helps in a quicker diagnosis of the infected patients in a shorter span of time. Methods: Nasopharyngeal swabs were collected from each patient and were processed in both Real-Time RT-PCR and ABBOTT ID NOWTM COVID-19 and the results are compared. Results: Out of the 87 samples tested in both Real-Time PCR and ABBOTT ID NOW, 74 samples were tested negative (85.1%) and 13 samples (14.9%) were tested positive in Real-Time PCR and 69 samples (79.3%) were tested negative and 18 samples (20.7%) were tested positive.82 samples (94%) results were found to be concordant with RT PCR results and 5 samples (6%) were found to have discordant results in both Real Time-PCR and ABBOTT ID NOW. The Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for ABBOTT ID NOW were found to be 72.2% and 100% respectively. Conclusion: The comparison between ABBOTT ID NOWTM and Real-Time PCR was found to be satisfactory. Hence, it can be used as a point of care testing in places where the resources are limited and swift results are anticipated. In addition, it offers extraordinarily good results in a low turnaround time for testing and can be considered not only in the healthcare set up but also as a best screening tool for passengers.
Abstract (English)
Background: The incidence of the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic has posed to be crisis to the diagnostic laboratories around the world for seeking reliable methods to confirm the infection in a short span of time which helps in the treatment plan and also to isolate the patients to prevent the spread. Most of the laboratories presently use Real-Time reverse transcription-Polymerase Chain Reaction (RT-PCR) test to diagnose the infection which has many drawbacks including the need for a dedicated work area, skillful and trained staffs and long testing time. In order to reduce the above constrains; we decided to test the efficiency of Abbott ID Now TM COVID-19 which is a cartridge based nucleic acid amplification assay that helps in a quicker diagnosis of the infected patients in a shorter span of time. Methods: Nasopharyngeal swabs were collected from each patient and were processed in both Real-Time RT-PCR and ABBOTT ID NOWTM COVID-19 and the results are compared. Results: Out of the 87 samples tested in both Real-Time PCR and ABBOTT ID NOW, 74 samples were tested negative (85.1%) and 13 samples (14.9%) were tested positive in Real-Time PCR and 69 samples (79.3%) were tested negative and 18 samples (20.7%) were tested positive.82 samples (94%) results were found to be concordant with RT PCR results and 5 samples (6%) were found to have discordant results in both Real Time-PCR and ABBOTT ID NOW. The Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for ABBOTT ID NOW were found to be 72.2% and 100% respectively. Conclusion: The comparison between ABBOTT ID NOWTM and Real-Time PCR was found to be satisfactory. Hence, it can be used as a point of care testing in places where the resources are limited and swift results are anticipated. In addition, it offers extraordinarily good results in a low turnaround time for testing and can be considered not only in the healthcare set up but also as a best screening tool for passengers.
Files
IJPCR,Vol15,Issue11,Article204.pdf
Files
(704.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:335f4dbb2ff9b825ee067ac45f111476
|
704.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-19
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue11,Article204.pdf
- Development Status
- Active
References
- 1. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, See B, Aguero-Rosenfeld ME. "Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution." J Clin Microbiol. (2020 Jul 23;58(8):e01136-20. doi: 10.1128/JCM.01136-20. PMID: 32471894; PMCID: PMC7383552.). 2. Ramachandran A, Noble J, Deucher A, Miller S, Tang PW, Wang RC. " Performance of Abbott ID-Now rapid nucleic amplification test for laboratory identification of COVID-19 in asymptomatic emergency department patients." Am Coll Emerg Physicians Open. (2021 Dec 29;2(6):e12592. doi: 10.1002/ emp 2.12592. PMID: 35005704; PMCID: PMC87 16572.). 3. Chaimayo, C., Kaewnaphan, B., Tanlieng, N. et al. "Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand." Virol J 17, 177 (2020). (https://doi.org/10.1186/s12985-020-01452-5). 4. Yuan-Po Tu, Jameel Iqbal, Timothy O'Leary. "Evaluation of ID NOW and RT-PCR for Detection of SARS-CoV-2 in an Ambulatory Population." medRxiv (2020.12.07.20245225; doi:https://doi.org/10.1101/2020.12.07.202452 25. 5. Farfour E, Asso-Bonnet M, Vasse M and SARS-CoV-2 Foch Hospital study group. "The ID NOW COVID-19, a high-speed highperformance assay." Eur J Clin Microbiol Infect Dis. (2021 Sep;40(9):2041-2045. doi: 10. 1007/s10096-021-04243-0. Epub 2021 Apr 15. PMID: 33855651; PMCID: PMC8046641.). 6. Babic N, Garner KS, Hirschhorn JW, Zebian R, Nolte FS. "Evaluation of Abbott ID NOW COVID-19 POC test performance characteristics and integration in the regional health network workflows to improve health care delivery." Clin Biochem. (2021 Dec 8:S0009-9120 (21)00320-9. doi: 10.1016/j.clinbiochem. 2021.12.003. PMID: 34896098; PMCID: PMC 8653396.).7. Shrestha LB, Pokharel K. Standard Operating Procedure for Specimen Collection, Packaging and Transport for Diagnosis of SARS-COV-2. JNMA J Nepal Med Assoc. 2020 Jul 31;58(228):627-629. doi: 10.31729/jnma.5260. PMID: 32968304; PMCID: PMC7580376. 8. Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A, Portnoy D, King T, Scott B, Pabbaraju K, Shokoples S, Wong AA, Gill K, Turnbull L, Hu J, Tipples G. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol. 2021 Jul;70(7):001372. doi: 10.1099/jmm.0.001372. PMID: 34309503; PMCID: PMC8493423. 9. Chheda Pratiksha, Dama Tavisha , Bhalerao Rahul , Bagwan Jamir , Bhat Devdatta , Shivaprakash Shashikala. "Comparative Study of the Efficacy of the Abbott ID Now Rapid Assay with Real Time PCR for the Detection of SARS-CoV-2 RNA." Sys Rev Pharm. (20. 10.2021). 10. ID NOW TM COVID-19 instructions for use – FDA https://www.fda.gov/media/136525/ download 11. artus® SARS-CoV-2 Prep&Amp™ UM Kit Instructions for Use (Handbook)https://www.qiagen.com/fi/resourc es/download.aspx?id=174afdd6-e789-4547- a6e6-a95a0eae486f&lang=en 12. Ward S, Lindsley A, Courter J, Assa'ad A. Clinical testing for COVID-19. J Allergy ClinImmunol. 2020 Jul; 146(1):23-34. doi: 10.1016/j.jaci.2020.05.012. Epub 2020 May 20. PMID: 32445839; PMCID: PMC7237919. 13. Srivastava S, Singh P, Malhotra R, Mathur P. Comparison of Abbott ID NOW, a novel isothermal amplification based COVID-19 diagnostic method with RTPCR. J Virol Methods. 2022 Jun;304:114521. doi: 10.1016/j.jviromet .2022.114521. Epub 2022 Mar 9. PMID: 3527 8535; PMCID: PMC8906026. 14. Pattnaik D, Poddar N, Pathi B K, et al. (February 21, 2022) Comparative Evaluation of Cartridge-Based Abbott ID NOW Test With ProbeBased Real-Time Reverse Transcription Polymerase Chain Reaction Assay for Detection of SARS-CoV-2. Cureus 14(2): e22470. doi:10.7759/cureus.22470. 15. Ismail G, Abdelhamid D, Abdelhalim R, Mostafa MS, Abdelghaffar H, Fahim NAE, Elshafei A, Naguib N. Comparison of Abbott ID NOW COVID-19 Rapid Molecular Assay to Allplex 2019-nCoV and VIASURE SARSCoV-2 Detection in Nasal Swabs. Open Access Maced J Med Sci [Internet]. 2022 May 6 [cited 2023 Feb. 28];10(A):930-7. Available from: https://oamjms.eu/index.php/ mjms/ article/view/9776 16. Elisa Burdino, Francesco Cerutti, Maria Grazia Milia, Tiziano Allice, Gabriella Gregori, Franco Aprà, Fabio De Iaco, Enzo Aluffi, Gianmatteo Micca, Valeria Ghisetti, Fast and reliable real life data on COVID-19 triaging with ID NOW, Journal of Clinical Virology Plus, Volume 2, Issue 1, 2022, 100065, ISSN 2667-0380, https://doi.org/10.1016/j.jcvp.2022. 100065. 17. Harrington A, Cox B, Snowdon J, Bakst J, Ley E, Grajales P, Maggiore J, Kahn S. "Comparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARSCoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients." J Clin Microbiol. (2020 Jul 23;58(8):e00798-20. doi: 10.1128 /JCM.00798-20. PMID: 32327448; PMCID: PMC7383519.). 18. Smithgall MC, Scherberkova I, Whittier S, Green DA. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. J ClinVirol. 2020 Jul;128:104428. doi: 10.1016/j.jcv.2020.104428. Epub 2020 May 13. PMID: 32434706; PMCID: PMC7217789. 19. Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. Prospective population-level validation of the Abbott ID NOW severe acute respiratory syndrome coronavirus 2 device implemented in multiple settings for testing asymptomatic and symptomatic individuals. ClinMicrobiol Infect. 2023 Feb;29(2):247-252. doi: 10.1016/j.cmi.2022.08.025. Epub 2022 Sep 10. PMID: 36096431; PMCID: PMC9463 071.